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 ABSTRACT 
 The objective of this study was to determine the effect 
of an injection of 10% butaphosphan and cyanocobala-
min (Catosal, Bayer, Shawnee Mission, KS) on the day 
of calving and 1 d later on the prevalence of subclinical 
ketosis in dairy cattle in the early postpartum period. 
Cows from 4 herds (n = 1,122) were randomized to 
receive either 25 mL of 10% butaphosphan and cyano-
cobalamin or 25 mL of sterile water subcutaneously on 
both days. Each milliliter of Catosal contained 0.05 mg 
of cyanocobalamin and 100 mg of butaphosphan, which 
provided 17.3 mg of P in the form of [1-(butylamino)-1-
methylethyl]-phosphonic acid. Serum was sampled for 
β-hydroxybutyrate (BHBA) concentration at calving 
(pretreatment) and again between 3 and 10 d in milk. 
A subset of samples from mature cows was also evalu-
ated for serum Ca and P concentrations. When cows 
from all age groups were included in the analysis, there 
was no difference between the median serum BHBA 
concentrations of cows in the 2 treatment groups, and 
no difference in the proportion of hyperketonemic cows 
(serum BHBA ≥1,200 μmol/L) during the first week 
postpartum. When the analysis was restricted to ma-
ture cows (lactation ≥3), both the median BHBA con-
centration and the proportion of hyperketonemic cows 
were significantly lower in the treatment group than 
in the placebo group. Serum Ca and P concentrations 
did not differ between treatment groups. Our results 
suggest that injection of butaphosphan and cyanocoba-
lamin on the day of calving and 1 d later may decrease 
the prevalence of subclinical ketosis during the week 
after calving in mature dairy cows, but not in first- and 
second-lactation animals. 
 Key words:   ketosis ,  β-hydroxybutyrate ,  butaphos-
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 INTRODUCTION 
 The transition from gestation to lactation is a period 
of great metabolic stress for dairy cows. Homeorhetic 
mechanisms in early lactation partition nutrients to-
ward the mammary gland to support lactation even at 
the expense of other body tissues. At the same time, 
voluntary DMI is markedly decreased. The drive for 
milk production continues despite insufficient energy 
intake and leads to negative energy balance in the 
postpartum cow. The postpartum period is the time of 
greatest risk of disease and culling, and cows with more 
severe and prolonged negative energy balance are at 
higher risk for both disease and culling (Rajala-Schultz 
and Grohn, 1999). 
 Ketosis commonly results either from the lack of suf-
ficient glucose precursors available for energy produc-
tion or from a reduced gluconeogenic capacity by the 
liver and is characterized by elevated concentrations of 
the ketone bodies acetoacetate, acetone, and BHBA in 
the blood, milk, and urine. Both clinical and subclini-
cal ketosis have been associated with other periparturi-
ent diseases, reduced milk yield, reduced first-service 
conception risk, and prolonged calving to conception 
intervals. Subclinical ketosis has been associated with 
clinical ketosis, metritis, cystic ovarian disease, and dis-
placed abomasum (Dohoo and Martin, 1984; LeBlanc 
et al., 2005). Dohoo and Martin (1984) also showed 
an association between positive milk ketone tests and 
reduced milk yields. Reproductive parameters have 
also been shown to be negatively affected by elevated 
BHBA. Work from Canada (Walsh et al., 2007) showed 
that cows that did not conceive to the first insemina-
tion were more likely to have elevated serum BHBA 
from 3 wk before to 9 wk after calving relative to cows 
that conceived to the first insemination. Also, elevated 
serum BHBA and NEFA and low blood glucose levels 
had negative effects on developing embryos and granu-
losa cells in vitro (Leroy et al., 2006; Vanholder et al., 
2006a,b). The direct and indirect effects of clinical and 
subclinical ketosis have a significant economic impact 
on dairy herds in North America. 
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Several treatments have been attempted to mitigate 
negative energy balance and its effects including oral 
drenching with propylene glycol and oral administration 
of monensin or monensin boluses. A study by Studer et 
al. (1993) in which cows were treated orally with pro-
pylene glycol for several days leading up to parturition 
showed no difference in postpartum serum BHBA con-
centrations between treated and control cows. Pickett 
et al. (2003) found that oral drenching with propylene 
glycol reduced plasma NEFA levels during the first 21 
d postpartum and tended to decrease concentrations 
of BHBA during the first 7 d postpartum. Duffield et 
al. (1998) studied the effect of a monensin controlled-
release capsule on preventing subclinical ketosis and 
found that monensin reduced the incidence, prevalence, 
and duration of subclinical ketosis compared with a 
placebo group. Overall, treatments meant to decrease 
the effects of subclinical ketosis have had limited suc-
cess, and more research in this area is warranted.
Catosal (Bayer, Shawnee Mission, KS) is a sterile 
solution containing 10% butaphosphan and cyanoco-
balamin (vitamin B12), and it is currently labeled as 
a veterinary tonic and metabolic stimulant for preven-
tion or treatment of deficiencies of vitamin B12 and P 
in cattle, horses, swine, and poultry. Each milliliter of 
Catosal contains 0.05 mg of cyanocobalamin and 100 
mg of butaphosphan, which provides 17.3 mg of P in 
the form of [1-(butylamino)-1-methylethyl]-phosphonic 
acid, an organic phosphoric acid compound. Methylma-
lonyl-CoA mutase is a vitamin B12-dependent enzyme 
that affects gluconeogenesis as a consequence of its role 
in the conversion of propionate to succinyl-CoA, which 
is required for entry into the Krebs (or tricarboxylic 
acid, TCA) cycle (Kennedy et al., 1990). Providing 
additional vitamin B12 could enhance the efficiency 
of energy production from propionate and result in 
a more active TCA cycle, thus potentially increasing 
gluconeogenesis. Phosphorus functions as an impor-
tant hydrogen buffering system in the blood and is a 
critical component of nucleic acids, adenosine triphos-
phate, and adenosine monophosphate (Cunningham, 
2002). Clinically, P is important because of its role in 
postparturient paresis in dairy cattle. Previous studies 
found that Catosal reduced postpartum disease inci-
dence and improved conception risk in South African 
dairy cattle (Palmer, 1980) and reduced stress-induced 
salivary cortisol response in pigs (Van Der Staay et 
al., 2007), but no studies have been reported on mod-
ern North American dairies. The association between 
elevated serum BHBA concentrations and postpartum 
disease, milk production, and reproductive efficiency is 
the source of recent and ongoing research efforts but 
the efficacy of this product in improving transition cow 
health and reducing the effect of negative energy bal-
ance is unknown.
We hypothesized that injections of 10% butaphos-
phan and cyanocobalamin would decrease serum BHBA 
concentrations and increase Ca and P concentrations. 
The objective of this study was to assess the effect of 
2 injections of 10% butaphosphan and cyanocobalamin 
on serum BHBA, Ca, and P concentrations of cows in 
the early postparturient period.
MATERIALS AND METHODS
Experimental Design
Cows in the study were enrolled between June 10 and 
August 17, 2008. The study was conducted on 4 dairy 
farms; 2 herds were located in Georgia and the other 
2 were in Wisconsin. Cows in all herds were housed 
in freestalls and fed a TMR. Milk, health, and repro-
ductive records for each herd were maintained on-farm 
with computerized dairy records systems (DairyComp 
305, Valley Ag Software, Tulare, CA; or PCDart, Dairy 
Records Management Systems, Raleigh, NC). The trial 
design was approved by the University of Georgia Col-
lege of Veterinary Medicine Clinical Research Commit-
tee and both the University of Georgia and University 
of Minnesota IACUC committees.
Based on detecting a treatment effect of a 12% reduc-
tion in serum BHBA at 1 wk postpartum and allowing 
for a 20% loss to follow-up, using a type I error of 0.05 
and a type II error of 0.20, we calculated a required 
sample size of 510 animals per treatment group, for 
a total of 1,020 animals. This estimate was based on 
a reduction in BHBA from 750 to 660 μmol/L, but 
the actual calculation was done using the natural 
log-transformed values (6.62 to 6.49 using a standard 
deviation of 0.67) because the raw BHBA data were 
not normally distributed. The data used for the sample 
size calculation were taken from previous work by the 
senior author.
Cows were enrolled in the study if they gave birth 
during the enrollment period and had a gestation length 
of at least 260 d. Within each herd, cows were stratified 
by parity (primiparous or multiparous) and then were 
randomly assigned using computer-generated random 
numbers to the treatment or placebo group based on 
calving order. Block randomization was used so that 
each sequential block of 6 animals in either parity 
group in each herd had an equal number of treatment 
and placebo-treated cows. The label for Catosal calls 
for an injection of 1 to 2 mL/100 lbs of BW, and for 
convenience and consistency across each of the 4 treat-
ment sites, a dose of 25 mL/cow was selected. Cows in 
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the treatment group received a subcutaneous injection 
of 25 mL of 10% butaphosphan and cyanocobalamin on 
the day of calving, and another subcutaneous injection 
of 25 mL of 10% butaphosphan and cyanocobalamin 
on the day after calving. Cows in the placebo group 
received a subcutaneous injection of 25 mL of sterile 
water on the day of calving, and another subcutane-
ous injection of 25mL of sterile water on the day after 
calving. Each subcutaneous injection was split into 3 
sites, with no more than 10 mL given per site, and 
given in the neck. The treatment and placebo solutions 
were provided by the manufacturer in coded bottles; 
farm personnel and study investigators were blinded 
to the code. Cows were body condition scored on the 
day of calving as described by Ferguson et al. (1994). 
A blood sample was collected aseptically from the coc-
cygeal vein from each cow within 24 h of calving (before 
treatment was given) using an evacuated sterile blood 
tube without anticoagulant (Vacutainer, Becton-Dick-
inson, Franklin Lakes, NJ) by farm personnel or study 
investigators. Blood collection and treatments were 
given each morning for cows that had calved within 
the last 24 h, so the initial sampling was conducted on 
either d 0 or d 1 following parturition. After clotting, 
samples were centrifuged for 10 min, and serum was 
removed and stored at −20°C until analysis. Cows in 
both groups were housed together, fed the same TMR, 
and managed per the normal farm routine. A member 
of the investigation team visited each farm at least once 
weekly on the same day and time to collect blood as 
above from all cows enrolled in the study and between 
3 and 10 d in milk. Blood was processed as above and 
stored at −20°C until analysis. All serum samples were 
submitted at one time for serum BHBA concentration 
to a commercial animal health laboratory (Michigan 
State University Diagnostic Center for Population and 
Animal Health, Lansing, MI) at the end of the study 
period. The BHBA was measured using an automated 
chemistry analyzer (AU 800, Olympus Diagnostics, 
Center Valley, PA) with a reagent supplied by Olympus 
Diagnostics.
A random subsample of 235 cows in the third lac-
tation and higher was taken for Ca and P analysis. 
From each farm, 50% of mature cows were randomly 
chosen from each treatment group, and serum samples 
from both sampling times were submitted to an animal 
diagnostic laboratory (University of Illinois, Urbana-
Champaign) for Ca and P determination. Calcium and 
P levels were measured using a Hitachi 917 (Roche Di-
agnostics, Indianapolis, IN) by means of a colorimetric 
technique following reactions of Ca with o-cresolphtha-
lein complexone in the presence of 8-hydroxyquinolone. 
Phosphorus levels were determined using the same 
equipment and similar technique following the forma-
tion of ammonium phosphomolybdate complex with 
ammonium molybdate by inorganic phosphate in the 
presence of sulfuric acid.
All cows were monitored by farm personnel for com-
mon diseases and conditions as described in Table 1. 
Disease definitions were adapted from previously pub-
lished work focusing on transition cows (LeBlanc et al., 
2002).
Data Management and Analysis
The distribution of serum BHBA concentrations 
(μmol/L) was right-skewed, so descriptive statistics 
were presented using the median and interquartile 
range. Nonparametric comparisons of treatment group 
medians were made using the Mann-Whitney test, 
and paired comparisons of different time points were 
made using the Wilcoxon signed rank test. Univariate 
comparison of the proportions of cows in each group 
with a serum BHBA ≥1,200 μmol/L during the week 
after calving were made using a chi-square test, and 
multivariable modeling of the dichotomized BHBA 
concentration was performed using logistic regression. 
Explanatory variables considered for the multivariable 
logistic regression models were: treatment, herd, lac-
tation number, BCS, dystocia, retained placenta, and 
twins. In addition, categories of dry period length (<40 
d, 40–70 d, or >70 d) were included for mature cows. 
Multivariable model selection was performed using a 
manual backward stepwise procedure. Variables were 
retained in the model if they had P < 0.1 or if their 
removal resulted in a change of ≥10% to the treatment 
coefficient. The treatment variable and a fixed herd 
effect were forced into all models regardless of their 
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Table 1. Case definitions1 
Disease Case definition
Twins Giving birth to 2 fully mature calves, either dead or alive
Dystocia Obstetrical difficulty requiring assistance; calving ease score of ≥3 on 5-point scale2
Retained placenta Fetal membranes that have not been expelled 24 h after calving
1Adapted from LeBlanc et al. (2002).
2Dystocia scores: 1 = no problem, 2 = slight assistance, 3 = needed assistance, 4 = considerable force, 5 = 
extreme difficulty.
significance. After reaching a preliminary main-effects 
model, all possible 2-way interactions with the treat-
ment variable were evaluated. Continuous variables 
were categorized to evaluate the assumption of linear-
ity in the log odds, and when the linearity assumption 
was not met categorical forms of continuous variables 
were used. The preferred categorization of continuous 
variables was determined by comparison of model likeli-
hoods using the Akaike information criterion (AIC). 
Model fit was evaluated using the Hosmer-Lemeshow 
goodness of fit test (Hosmer and Lemeshow, 2000).
Median Ca and P concentrations were compared 
between treatment groups using the Mann-Whitney 
test, and the concentrations at different time points 
were compared using the Wilcoxon signed rank test. 
All tests were performed assuming a 2-sided alternative 
hypothesis and P-values <0.05 were considered statisti-
cally significant. Analyses were performed using com-
mercially available statistical software (Stata version 
10.1, StataCorp LP, College Station, TX).
RESULTS
A total of 1,190 animals were enrolled at calving. 
Forty-six animals had only 1 serum sample taken, 3 
animals had more than 1 sample in one day, 15 ani-
mals were sampled at 2 DIM or after 10 DIM, and the 
electronic records of 4 cows were unavailable. These 
animals were not included in the analysis, which left 
565 cows in the treatment group and 557 in the con-
trol group. Randomization yielded treatment groups 
that were similar with respect to the distribution of 
cow characteristics at the time of treatment assign-
ment (Table 2). The prevalence of twinning, dystocia, 
and retained placenta were similar to that in previous 
reports and were uniform across herds. The reported 
incidence of retained placenta was much lower in one 
herd compared with the other 3 herds (0.2% vs. 8.97%; 
P < 0.01). The day on which the wk 1 serum sample 
was taken was not different between the treatment and 
control groups (median of 6 d for both groups; P = 
0.53). There were no local or systemic adverse effects 
observed as a result of either the treatment or control 
injections in any animals.
Analysis Including Cows from All Age Groups
The distribution of serum BHBA concentrations by 
treatment group and time of sample collection is shown 
in Figure 1, and descriptive statistics are summarized 
in Table 3. There was no difference between the median 
BHBA concentrations of treated and control groups 
pretreatment (Mann-Whitney, P = 0.61) or during the 
first week postpartum (Mann-Whitney, P = 0.42), al-
though there was an increase in the median BHBA con-
centrations of both groups between the first and second 
measurements (Wilcoxon signed-rank, P < 0.001).
Similarly, there was no difference in the crude pro-
portions of cows in the treatment or placebo groups 
with a serum BHBA ≥1,200 μmol/L during the week 
after calving [68/565 (12.0%) and 81/557 (14.5%), 
respectively; chi-square, P = 0.22]. In a multivariable 
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Table 2. Distribution of 1,122 cows enrolled in a randomized placebo-controlled trial by cow characteristics 
and treatment assignment 
Variable Category
Treatment group
P-value2Placebo, n (%) BTP+B12,1 n (%)
Herd Herd 1 (GA) 83 (14.9) 85 (15.0) 1.00
Herd 2 (GA) 65 (11.7) 64 (11.3)
Herd 3 (WI) 145 (26.0) 149 (26.4)
Herd 4 (WI) 264 (47.4) 267 (47.3)
Lactation 1 162 (29.1) 163 (28.9) 0.69
2 167 (30.0) 158 (28.0)
3+ 228 (40.9) 244 (43.2)
BCS ≤3 233 (41.8) 233 (41.2) 0.93
3.25–3.75 233 (41.8) 246 (43.5)
4+ 33 (5.9) 32 (5.7)
Not recorded 58 (10.4) 54 (9.6)
Dystocia No 502 (90.1) 514 (91.0) 0.63
Yes 55 (9.9) 51 (9.0)
Retained placenta No 529 (95.0) 539 (95.4) 0.74
Yes 28 (5.0) 26 (4.6)
Twins No 518 (93.0) 537 (95.0) 0.15
Yes 39 (7.0) 28 (5.0)
Total  557 (100.0) 565 (100.0)  
110% butaphosphan + cyanocobalamin (Catosal, Bayer, Shawnee Mission, KS).
2Chi-square test of independence.
analysis of the dichotomized BHBA concentrations, 
there was also no significant effect of treatment, but 
lactation number, BCS, dystocia, and having a retained 
placenta were all significant predictors (Table 4). The 
odds of having a serum BHBA ≥1,200 μmol/L during 
the week after calving were 3.6 times higher for cows 
that were in their third or higher lactation compared 
with first-lactation cows, 3 times higher for cows with 
a BCS ≥4 compared with those with a BCS ≤3, twice 
as high for cows that had experienced dystocia, and 
4.2 times higher for cows that had a retained placenta. 
All treatment × variable interactions added to the fi-
nal model summarized in Table 4 were nonsignificant: 
treatment × herd (P = 0.22), treatment × lactation 
(P = 0.14), treatment × BCS (P = 0.50), treatment × 
dystocia (P = 0.28), and treatment × retained placenta 
(P = 0.64).
Analysis Restricted to Mature Cows
Because older cows were more likely to have a serum 
BHBA ≥1,200 μmol/L, and because they are consid-
ered to be at increased risk for developing ketosis, a 
subgroup analysis was performed to evaluate the effect 
of treatment in cows that were in their third or higher 
lactation (Table 5). Although the BHBA concentra-
tions of mature cow groups did not differ pretreatment 
(Mann-Whitney, P = 0.67), the treated group did have 
a lower median BHBA concentration than the placebo 
group during the week after calving (Mann-Whitney, 
P = 0.047). As was the case when cows from all pari-
ties were included in the analysis, the medians of both 
treatment groups increased significantly between the 
pre- and posttreatment measurements (Wilcoxon 
signed-rank, P < 0.001).
Consistent with the comparison of BHBA concentra-
tions on a continuous scale, the proportion of mature 
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Figure 1. Distribution of serum BHBA concentrations at the baseline (d 0–1) and follow-up (d 3–10) sample collections for all cows receiv-
ing either placebo (n = 557) or 10% butaphosphan + cyanocobalamin (BTP+B12; Catosal, Bayer, Shawnee Mission, KS; n = 565). The last 
category includes all cows with a serum BHBA ≥2,800 μmol/L.
Table 3. Median (interquartile range) serum BHBA concentrations 
(μmol/L) at the baseline (d 0–1) and follow-up (d 3–10) sample 
collections for all cows randomly assigned to receive either placebo or 
BTP+B12 
Treatment n d 0–1 d 3–10
Placebo 557 428a (314, 566) 585b (428, 862)
BTP+B121 565 425a (325, 575) 560b (441, 791)
a,bWithin rows and columns, medians with a superscript in common 
are not significantly different at a level of significance of 5%.
110% butaphosphan + cyanocobalamin (Catosal, Bayer, Shawnee 
Mission, KS).
cows with a serum BHBA ≥1,200 μmol/L during the 
week after calving was significantly lower in the treated 
group than in the placebo group [48/244 (19.7%) vs. 
66/228 (29.0%); P = 0.019]. In the multivariable analy-
sis, mature cows in the treatment group had 40% lower 
odds of having a serum BHBA ≥1,200 μmol/L dur-
ing the week after calving than cows that received the 
placebo, after adjusting for the other variables in the 
model (Table 6). The odds of having a serum BHBA 
≥1,200 μmol/L were 3.8 times higher in mature cows 
with a BCS ≥4 than in those with a BCS ≤3, and 
5.9 times higher in cows that had a retained placenta. 
Dystocia was not associated with having a high BHBA 
concentration in mature cows. Dry period length was 
not evaluated as a covariate in the analysis of cows 
from all parity groups because this variable was not 
relevant for cows in the first lactation. In the analysis 
of mature cows, however, those with a dry period >70 
d had approximately twice the odds of having a BHBA 
≥1,200 μmol/L compared with cows with a dry period 
length of 40 to 70 d. All treatment × variable interac-
tions added to the final model summarized in Table 
6 were nonsignificant: treatment × herd (P = 0.70), 
treatment × BCS (P = 0.85), treatment × dry period 
length (P = 0.91), and treatment × retained placenta 
(P = 0.66).
Serum samples submitted from 3 of the 235 mature 
cows with Ca and P determinations were excluded from 
the analysis because electronic records for these cows 
were unavailable. Serum Ca and P concentrations for 
the remaining 232 cows are summarized in Table 7. The 
median Ca concentrations of both treatment groups in-
creased significantly (P < 0.001) between the baseline 
and follow-up measurements, but there was no signifi-
cant difference between groups at pretreatment (P = 
0.41) or posttreatment (P = 0.13). Likewise, the median 
P concentrations of both groups also increased signifi-
cantly (P < 0.003) between the baseline and follow-up 
measurements, and the difference between groups was 
nonsignificant both pretreatment (P = 0.065) and post-
treatment (P = 0.054). Although the difference between 
groups with respect to their P concentrations was close 
to achieving statistical significance, the magnitude of 
the posttreatment difference was similar to that of 
the pretreatment difference. The median increase in P 
concentration between baseline and follow-up for the 
placebo group (0.65 mg/dL) did not differ from the 
median increase for the treated group (0.65 mg/dL; P 
= 0.66), suggesting that any difference between groups 
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Table 4. Multivariable logistic regression model predicting serum BHBA ≥1,200 μmol/L at the posttreatment 
sampling (d 3–10) for 1,010 cows with complete covariate information1 
Variable Coefficient (SE) Odds ratio (95%CI) P-value2
Treatment BTP+B123 −0.276 (0.194) 0.76 (0.52, 1.1) 0.15
Herd   0.25
 Herd 1 (Georgia) Referent Referent Referent
 Herd 2 (Georgia) −0.729 (0.448) 0.48 (0.20, 1.2) 0.10
 Herd 3 (Wisconsin) −0.523 (0.303) 0.59 (0.33, 1.1) 0.084
 Herd 4 (Wisconsin) −0.340 (0.272) 0.71 (0.42, 1.2) 0.21
Lactation   <0.001
 1 Referent Referent Referent
 2 −0.707 (0.391) 0.49 (0.23, 1.1) 0.071
 3+ 1.27 (0.261) 3.6 (2.1, 5.9) <0.001
BCS   0.010
 ≤3 Referent Referent Referent
 3.25–3.75 0.432 (0.227) 1.5 (1.0, 2.4) 0.057
 4+ 1.11 (0.369) 3.0 (1.5, 6.3) 0.003
Dystocia 0.754 (0.320) 2.1 (1.1, 4.0) 0.018
Retained placenta 1.42 (0.361) 4.2 (2.0, 8.4) <0.001
Constant −2.44 (0.409) NC4 <0.001
1Hosmer-Lemeshow goodness of fit (P = 0.673).
2Based on Wald statistics.
310% butaphosphan + cyanocobalamin (Catosal, Bayer, Shawnee Mission, KS).
4Not calculated.
Table 5. Median (interquartile range) serum BHBA concentrations 
(μmol/L) at the baseline (d 0–1) and follow-up (d 3–10) sample 
collections for mature cows (lactation ≥3) randomly assigned to 
receive either placebo or BTP+B12 
Treatment n d 0–1 d 3–10
Placebo 228 497a (384, 646) 756b (533, 1,263)
BTP+B121 244 500a (376, 674) 683c (512, 956)
a–cWithin rows and columns, medians with a superscript in common 
are not significantly different at a level of significance of 5%.
110% butaphosphan + cyanocobalamin (Catosal, Bayer, Shawnee 
Mission, KS).
was likely caused by the random selection process and 
not related to treatment response.
DISCUSSION
This is the first large-scale randomized blinded trial 
to evaluate the effects of an injectable product con-
taining butaphosphan and cyanocobalamin on modern 
North American dairies. The focus of this study was to 
quantify the effect of treatment on the day of calving 
and 1 d later on serum BHBA concentrations in dairy 
cattle during the early postpartum period. Although no 
difference was observed between treatment and placebo 
groups in the analysis of cattle from all age groups, the 
findings do suggest that treatment may have a benefi-
cial effect in reducing the risk of hyperketonemia during 
the week after calving in mature cows. This does not 
necessarily imply, however, that a decrease in serum 
BHBA concentration of the magnitude observed in this 
study corresponds to any meaningful improvements in 
mature cattle health or production. Health and produc-
tion parameters through the first 150 DIM for cattle 
enrolled in this study will be examined in a separate 
paper to evaluate their association with serum BHBA 
concentrations and with treatment group status.
In practice, serum BHBA concentrations are typi-
cally dichotomized to distinguish between normal and 
hyperketonemic cattle, with frequently recommended 
cutpoints of 1,000 to 1,400 μmol/L (Geishauser et al., 
1997; LeBlanc et al., 2005). In a recent study that 
empirically examined a wide range of possible cut-off 
values for BHBA concentration, it was reported that 
during the first week after calving, 1,200 μmol/L was 
the optimum point for predicting an increased likeli-
hood of adverse health outcomes including displaced 
abomasum and metritis based on the greatest sum of 
sensitivity and specificity (Duffield et al., 2009). Within 
the Duffield study, there was also a strong association 
Journal of Dairy Science Vol. 93 No. 3, 2010
ROLLIN ET AL.984
Table 6. Multivariable logistic regression model predicting serum BHBA ≥1,200 μmol/L at the posttreatment 
sampling (d 3–10) for 436 mature cows (lactation ≥3) with complete covariate information1 
Variable Coefficient (SE) Odds ratio (95%CI) P-value2
Treatment BTP+B123 −0.508 (0.235) 0.60 (0.38, 0.95) 0.031
Herd   0.023
 Herd 1 (Georgia) Referent Referent Referent
 Herd 2 (Georgia) −0.584 (0.608) 0.56 (0.17, 1.8) 0.34
 Herd 3 (Wisconsin) −0.687 (0.373) 0.50 (0.24, 1.0) 0.065
 Herd 4 (Wisconsin) 0.357 (0.343) 1.4 (0.73, 2.8) 0.30
BCS   0.008
 ≤3 Referent Referent Referent
 3.25–3.75 0.543 (0.280) 1.7 (1.0, 3.0) 0.053
 4+ 1.33 (0.432) 3.8 (1.6, 8.9) 0.002
Dry period length (d)   0.023
 40–70 Referent Referent Referent
 0–39 −0.355 (0.316) 0.70 (0.38, 1.3) 0.26
 71+ 0.615 (0.300) 1.9 (1.0, 3.3) 0.040
Retained placenta 1.77 (0.461) 5.9 (2.4, 14) <0.001
Constant −1.40 (0.365) NC4 <0.001
1Hosmer-Lemeshow goodness of fit (P = 0.682).
2Based on Wald statistics.
310% butaphosphan + cyanocobalamin (Catosal, Bayer, Shawnee Mission, KS).
4Not calculated.
Table 7. Median (interquartile range) serum calcium and phosphorus concentrations of mature cows (lactation 
≥3) by treatment group and the number of days in milk (d 0–1 or d 3–10) at the time of sample collection 
Treatment group n
Calcium (mmol/L) Phosphorus (mmol/L)
d 0–1 d 3–10 d 0–1 d 3–10
Placebo 112 2.09a 2.31b 1.45a 1.71b
(1.93, 2.24) (2.16, 2.45) (1.20, 1.86) (1.42, 2.03)
BTP+B121 120 2.11a 2.35b 1.62a 1.82b
(1.94, 2.30) (2.20, 2.53) (1.34, 1.91) (1.57, 2.13)
a,bWithin rows and columns, medians with a superscript in common are not significantly different at a level of 
significance of 5%.
110% butaphosphan and cyanocobalamin (Catosal, Bayer, Shawnee Mission, KS).
between the 1,200 μmol/L cutpoint and risk of subse-
quent clinical ketosis and decreased milk production. 
As a consequence of this work and others, the 1,200 
μmol/L level for BHBA was used to define hyperke-
tonemia in the current analysis, and cows with a serum 
BHBA ≥1,200 μmol/L at any point during d 3 to 10 
following calving were considered to have subclinical 
ketosis.
In the multivariable analysis that included cows from 
all age groups, cows in their second lactation had a 
lower risk of subclinical ketosis than first-lactation cows, 
which was expected because of their lower risk of dysto-
cia and metabolic disease (Curtis et al., 1985; Djemali 
et al., 1987; Rajala and Grohn, 1998), and cows in their 
third lactation and higher were at increased risk. Cows 
with a BCS ≥4 were at increased risk for subclinical 
ketosis compared with cows with a BCS ≤3. High BCS 
cows have a greater decrease in DMI around calving 
(Hayirli et al., 2002), and have the ability to mobilize 
more fat, which is converted to NEFA and eventually 
ketone bodies. Dystocia was associated with the risk 
of subclinical ketosis when cows from all lactations 
were included, but did not have an effect when only 
mature cows were included. This difference may be be-
cause of the difference in detection of dystocia in older 
animals (low frequency) compared with first-lactation 
animals, resulting in an inability to detect a significant 
association with subclinical ketosis. Retained placenta 
had a strong association with subclinical ketosis, likely 
because of its strong association with decreased pre-
partum feed intake, energy balance challenges, and 
the consequent compromised immune function in the 
periparturient cows that has been shown to increase the 
risk of retained placenta (Kimura et al., 2002).
The association between dry period length and sub-
clinical ketosis was not evaluated in the multivariable 
analysis that included animals from all age groups 
because including this variable would have excluded 
first-lactation animals. In the analysis of mature cows, 
however, animals having a long dry period (>70 d) were 
at increased risk of subclinical ketosis compared with 
those with a normal (40–70 d) dry period length, even 
after adjusting for BCS. The effect of longer dry peri-
ods, regardless of BCS, supports recent work describ-
ing the various metabolic changes that can occur with 
prolonged ad libitum feeding of far dry cows (cows that 
are more than 21–28 d before calving). Cows fed for ad 
libitum DMI during the far dry period tend to over-
consume energy relative to their requirements resulting 
in peripartum lipid metabolism problems (Douglas et 
al., 2006) and may be at greater risk for development 
of insulin resistance challenges (Dann et al., 2006). If 
overfeeding during a normal far dry period can result 
in insulin resistance and lipid metabolism challenges, 
prolonged far dry periods may potentially exacerbate 
this issue.
No differences were detected in serum Ca or serum P 
concentrations between placebo and treatment groups 
at calving or during the following week. This may be 
because of the timing of serum sampling, homeostatic 
control of circulating concentrations of these minerals, 
or because the product truly had no supplemental ef-
fect on serum Ca and P levels. The calculated level of 
P supplementation provided by 25 mL of Catosal was 
only 0.43 g, and the recommended dose for treatment 
of clinical hypophosphatemia is 6 g of P provided by 23 
g of monosodium phosphate dissolved in 1 L of saline 
(Goff, 2004).
Previous studies have focused on the use of butaphos-
phan and cyanocobalamin in ill animals. For example, 
a German study utilizing butaphosphan and cyanoco-
balamin as a postsurgical therapy following surgical 
correction of left displaced abomasum showed improved 
rumen motility in cows receiving the product (Furll et 
al., 2006). However, because the exact mechanism of 
action of butaphosphan and cyanocobalamin in overall 
energy metabolism in the periparturient dairy cow is 
still unknown, it is difficult to speculate on how to best 
implement this therapeutic tool.
Few data are available on the proposed mechanisms 
of action of butaphosphan and cyanocobalamin. A less 
severe drop in DMI, improved gluconeogenesis, and di-
minished lipolysis in the time surrounding calving would 
lessen the depth and length of negative energy balance 
in early lactation, but no data exist that show this ef-
fect by butaphosphan and cyanocobalamin in combina-
tion. It is well known that the liver of the periparturient 
dairy cow experiences tremendous adaptations at the 
onset of lactation and that most dairy cattle experience 
some degree of hepatic lipidosis (Drackley et al., 2001; 
Hayirli, 2006). Improving overall liver health and its 
ability to process energy could have a potential effect 
on negative energy balance in early lactation.
Cyanocobalamin is a co-enzyme involved in the 
TCA cycle and in methionine synthesis. Ruminants 
are generally supplied with adequate vitamin B12 from 
ruminal microbes. Although cyanocobalamin is not 
normally added to diets, the expected requirement for 
dairy cattle is 0.34 to 0.68 μg/kg of live weight (NRC, 
2001) or 0.2 to 0.5 mg for most Holsteins. The treat-
ment used in the current study provided 1.25 mg of B12 
per injection for 2 consecutive days for a total of 2.5 
mg of supplemental B12. A deficiency of vitamin B12 
could affect the efficiency of energy production from 
propionate and from NEFA. With greater propionate 
production as a result of a more active TCA cycle, not 
only should gluconeogenesis be increased, but because 
of the positive effect of elevated glucose on insulin and 
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its ability to block lipolysis, one might expect altered 
fatty acid metabolism through reduction in both he-
patic ketogenesis and hepatic lipidosis. Vitamin B12 is 
also involved with the synthesis of methionine, a methyl 
donor for compounds such as choline and carnitine, and 
these 2 compounds are involved with fat metabolism 
and transport. In support of these concepts, recent work 
with supplementary folic acid and vitamin B12 dem-
onstrated increased glucose availability and decreased 
accumulation of hepatic lipids in periparturient dairy 
cattle (Preynat et al., 2009). However, this work used 
a 10-mg dose of vitamin B12 repeated weekly, which 
was 8 times the dose used per daily treatment in the 
current study.
Butaphosphan is 1-butylamino-1-methylethyl phos-
phonic acid, an organic phosphoric acid compound that 
has been used as a phosphorus source in cattle, horses, 
pigs, sheep, and goats and that may aid liver metabo-
lism by donating P for ATP synthesis. Additionally, 
clinical and especially subclinical hypocalcemia are 
common problems in periparturient dairy cattle and 
strategic supplementation with P would be expected 
to help with Ca homeostasis, which should serve to 
improve smooth muscle function in the gastrointestinal 
tract and uterus, stimulate feed intake, improve im-
mune function, and help to reduce the magnitude and 
severity of negative energy balance. However, there cur-
rently are no data to support this supposition.
Several studies have investigated the effect of different 
interventions on serum BHBA concentrations during 
the postpartum period. A well-designed controlled study 
using monensin controlled-release capsules placed in the 
rumen prepartum found that this practice reduced the 
incidence and prevalence of subclinical ketosis (Duffield 
et al., 1998). Another study with fewer animals enrolled 
found similar effects of a monensin controlled-release 
capsule during the dry period (Melendez et al., 2004). 
Other investigators have investigated the administration 
of propionate precursors to affect energy metabolism in 
the peripartal period. Pickett et al. (2003) administered 
propylene glycol orally for the first 3 d postpartum and 
found it tended to decrease serum BHBA concentra-
tions for the first 7 d. A study by Butler et al. (2006) 
found that daily oral treatment with propylene glycol 
from 10 d prepartum to 25 d postpartum reduced se-
rum BHBA concentrations during that period. Overall, 
there are few treatments that are approved for use in 
dairies in the United States that have shown an effect 
in reducing subclinical ketosis.
In this study, no differences were seen in the BHBA 
concentrations of treated and control cows when all age 
groups were included in the analysis, but differences 
were seen in mature cows. Based on these results, a 
metaphylactic approach to preventing subclinical keto-
sis with butaphosphan and cyanocobalamin in all cows 
is not recommended. The product may be more likely 
to yield a benefit when used in animals known to be at 
higher risk of developing ketosis, such as older animals, 
those with long dry periods, high BCS, or retained pla-
centa, or those experiencing dystocia.
However, even within the mature cow groups, the mag-
nitude of the difference detected between treated and 
control animals was small and the true effect on health 
and productivity of decreasing BHBA concentrations 
by this amount is unknown. Because subclinical ketosis 
has been shown to increase the risk for other costly 
diseases such as metritis and displaced abomasum, even 
small decreases in the prevalence of hyperketonemia 
might have beneficial effects on the incidence of other 
diseases. If so, an early intervention like the one used in 
this study might result in a positive economic benefit, 
but this remains to be determined.
Strengths of the current study include the prospective, 
blinded design, the use of 4 different herds representa-
tive of typical, contemporary management practices 
from 2 distinct regions of the country, and objective 
outcomes. Unfortunately, details regarding specific nu-
trient fractions in each herd’s diets were not obtained 
and because of budgetary limitations, vitamin B12 sta-
tus before and after treatment was not measured.
Subclinical ketosis is an economic and welfare chal-
lenge for modern North American dairies because of its 
association with decreased milk production, decreased 
reproductive efficiency, and increased incidence of other 
disease. Having more validated interventions available 
to prevent or treat this costly condition will improve 
the economic viability of dairy producers and improve 
animal health as a whole.
CONCLUSIONS
Our results suggest that a metaphylactic injection of 
10% butaphosphan and cyanocobalamin on the day of 
calving and 1 d later may decrease the prevalence of 
subclinical ketosis during the first week postpartum in 
mature dairy cows, but not in first- and second-lactation 
cows. Serum Ca and P concentrations were not affected 
by treatment with butaphosphan and cyanocobalamin. 
More research is needed to assess the efficacy of this 
product in reducing periparturient disease, improving 
milk production, and improving reproductive efficiency. 
These outcomes will provide a more valid assessment of 
the potential economic value of the product.
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